Lifesci Capital Has Bullish Estimate for DYN Q1 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Stock analysts at Lifesci Capital upped their Q1 2026 earnings per share (EPS) estimates for Dyne Therapeutics in a report issued on Monday, March 2nd. Lifesci Capital analyst F. Brisebois now expects that the company will earn ($0.76) per share for the quarter, up from their previous forecast of ($0.77). The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. Lifesci Capital also issued estimates for Dyne Therapeutics’ Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.83) EPS and Q4 2026 earnings at ($0.86) EPS.

DYN has been the subject of a number of other research reports. Royal Bank Of Canada boosted their price target on Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Oppenheimer raised Dyne Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $11.00 to $40.00 in a research report on Wednesday, December 10th. Sanford C. Bernstein set a $23.00 price objective on Dyne Therapeutics in a research report on Tuesday, December 9th. JPMorgan Chase & Co. decreased their price objective on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Finally, Robert W. Baird set a $30.00 price objective on shares of Dyne Therapeutics in a research note on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.00.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $15.23 on Thursday. The company has a quick ratio of 13.47, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. The firm has a 50-day simple moving average of $17.26 and a 200 day simple moving average of $17.04. Dyne Therapeutics has a fifty-two week low of $6.36 and a fifty-two week high of $25.00. The company has a market cap of $2.51 billion, a PE ratio of -4.30 and a beta of 1.34.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02).

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently bought and sold shares of the company. Chung Wu Investment Group LLC bought a new position in Dyne Therapeutics during the third quarter worth about $30,000. Strs Ohio bought a new position in shares of Dyne Therapeutics in the 4th quarter valued at about $51,000. CWM LLC increased its position in shares of Dyne Therapeutics by 168.1% during the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after purchasing an additional 1,900 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Dyne Therapeutics during the fourth quarter worth $84,000. Finally, Steward Partners Investment Advisory LLC raised its stake in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.